Timothy M. Mayleben, President & CEO at Esperion Therapeutics, Inc. (ESPR), bought 7,000 shares at $14.85 ($104K) on 2016-05-04, disclosed to the SEC on 2016-05-05.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| ESPR | BUY | 2019-11-08 | $370K | — | Filing → |
| ESPR | BUY | 2019-09-06 | $259K | — | Filing → |
| ESPR | BUY | 2019-08-02 | $198K | — | Filing → |